Drug Profile
Research programme: diagnostic imaging agents - Affibody
Alternative Names: ABY-028; Her2-targeted PET imaging agent - Affibody/GE Healthcare; PDL1-targeted PET imaging agent - Affibody/GE HealthcareLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Affibody; GE Healthcare
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Gastric cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Breast-cancer(Diagnosis) in Sweden
- 28 Sep 2021 No recent reports of development identified for research development in Gastric-cancer(Diagnosis) in Sweden
- 23 Sep 2019 Preclinical development is still ongoing for Breasr cancer in Sweden